Literature DB >> 4056869

Astrocytomas of the spinal cord in children and adolescents.

R Reimer, B M Onofrio.   

Abstract

The authors review 32 cases of spinal cord astrocytoma in patients under 20 years of age who were treated at the Mayo Clinic between 1955 and 1980. There was a 1.3:1 male to female ratio. Twenty patients were between 6 and 15 years of age at the time of diagnosis. The duration of symptoms prior to definitive diagnosis varied from 5 days to 9 years, with an average of 24 months. The most common symptoms were pain (62.5%), gait disturbance (43.7%), numbness (18.8%), and sphincteric dysfunction (18.8%). The most common neurological findings were a Babinski response (50.0%), posterior column sensory dysfunction (40.6%), and paraparesis (37.5%). A median follow-up period of 8.6 years (range 0.8 to 25.5 years) revealed that the survival time diminished with increased histological grade of the astrocytoma (p less than 0.001). The development of postlaminectomy spinal deformities represented a serious postoperative complication. This occurred in 13 patients and was first recognized between 8 and 90 months postoperatively. Six deformities occurred following cervical laminectomy, and eight patients required at least one orthopedic procedure. It is crucial to follow these patients for an extended period of time to watch for postoperative spinal deformities.

Entities:  

Mesh:

Year:  1985        PMID: 4056869     DOI: 10.3171/jns.1985.63.5.0669

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  30 in total

Review 1.  Radiation therapy and the management of intramedullary spinal cord tumors.

Authors:  S R Isaacson
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Freiburg neuropathology case conference: an intramedullary mass lesion in a child.

Authors:  O Moske-Eick; C A Taschner; S Krauss; J Kirschner; V van Velthoven; C Rottenburger; J Rössler; M Prinz
Journal:  Clin Neuroradiol       Date:  2010-06       Impact factor: 3.649

3.  Removal of intradural-extramedullary spinal cord tumors with unilateral limited laminectomy.

Authors:  Jong-Eun Sim; Seung-Jin Noh; Young-Jin Song; Hyung-Dong Kim
Journal:  J Korean Neurosurg Soc       Date:  2008-05-20

Review 4.  Prognostic factors in intramedullary astrocytomas: a literature review.

Authors:  Vladimír Benes; Pavel Barsa; Vladimír Benes; Petr Suchomel
Journal:  Eur Spine J       Date:  2009-06-28       Impact factor: 3.134

5.  Unilateral hemilaminectomy for patients with intradural extramedullary tumors.

Authors:  Cai-xing Sun; Xu-li Meng; Shang-nao Xie; Yang Yu; Hong-jian Yang; Bin Wu
Journal:  J Zhejiang Univ Sci B       Date:  2011-07       Impact factor: 3.066

6.  Treatment, prognostic factors, and outcomes in spinal cord astrocytomas.

Authors:  Mohamad H Fakhreddine; Anita Mahajan; Marta Penas-Prado; Jeffrey Weinberg; Ian E McCutcheon; Vinay Puduvalli; Paul D Brown
Journal:  Neuro Oncol       Date:  2013-01-14       Impact factor: 12.300

7.  Anaplastic astrocytoma of the spinal cord presenting with features of raised intracranial pressure.

Authors:  A K Purohit; I Dinakar; C Sundaram; K S Ratnakar
Journal:  Childs Nerv Syst       Date:  1990-03       Impact factor: 1.475

8.  Spinal cord tumors: gadolinium-DTPA-enhanced MR imaging.

Authors:  M C Chamberlain; A D Sandy; G A Press
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

Review 9.  Paediatric spinal glioblastoma: case report and review of therapeutic strategies.

Authors:  Philip J O'Halloran; Michael Farrell; John Caird; Michael Capra; David O'Brien
Journal:  Childs Nerv Syst       Date:  2013-01-15       Impact factor: 1.475

10.  Primary spinal cord tumors of childhood: effects of clinical presentation, radiographic features, and pathology on survival.

Authors:  John R Crawford; Alejandra Zaninovic; Mariarita Santi; Elisabeth J Rushing; Cara H Olsen; Robert F Keating; Gilbert Vezina; Nadja Kadom; Roger J Packer
Journal:  J Neurooncol       Date:  2009-06-12       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.